SCHEMBL8733277

SCHEMBL8733277

CCCCCCOc1ccc(NC(C)=O)cc1

nearest known ligand 0.68

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
FAAH O00519 14/20 0.68
LMNA P02545 2/20 0.68
SMN1; SMN2 Q16637 1/20 0.68
MEN1 O00255 1/20 0.68
CYP1A2 P05177 1/20 0.68
KMT2A Q03164 1/20 0.68
TDP1 Q9NUW8 1/20 0.68
ALDH1A1 P00352 1/20 0.67
GAA P10253 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
MAPT P10636 1/20 0.62
HPGD P15428 1/20 0.61
RECQL P46063 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16316826 1.00 FAAH (0.68) FAAHLMNASMN1; SMN2MEN1CYP1A2
SCHEMBL9885419 1.00 FAAH (0.68) FAAHLMNASMN1; SMN2MEN1CYP1A2
SCHEMBL7491784 0.98 LMNA (0.70) FAAHLMNASMN1; SMN2MEN1CYP1A2
SCHEMBL3223930 0.95 LMNA (0.74) FAAHLMNASMN1; SMN2MEN1CYP1A2
SCHEMBL9570672 0.93 ALDH1A1 (0.75) FAAHLMNASMN1; SMN2MEN1CYP1A2
SCHEMBL9570550 0.93 ALDH1A1 (0.75) FAAHLMNASMN1; SMN2MEN1CYP1A2
SCHEMBL18405957 0.92 FAAH (0.63) FAAHLMNASMN1; SMN2MEN1CYP1A2
SCHEMBL5820622 0.89 LMNA (0.67) FAAHLMNASMN1; SMN2MEN1CYP1A2
SCHEMBL1133893 0.88 KMT2A (0.74) FAAHLMNASMN1; SMN2MEN1CYP1A2
SCHEMBL10802880 0.88 ALDH1A1 (0.77) FAAHLMNASMN1; SMN2MEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207222-B2 Nitric oxide releasing derivatives of paracetamol COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2012-06-26 US disclosed
US-20100234472-A1 NITRIC OXIDE RELEASING DERIVATIVES OF PARACETAMOL COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH 2010-09-16 US disclosed
WO-2009024998-A1 NITRIC OXIDE RELEASING DERIVATIVES OF PARACETAMOL COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2009-02-26 WO disclosed
US-20070078146-A1 Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma PHARMACIA CORPORATION 2007-04-05 US disclosed
WO-1998043649-A2 AGE PRODUCTION INHIBITORY COMPOSITION COMPRISING A MAILLARD REACTION INHIBITOR AND VITAMIN B¿6? OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1998-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234472-A1 NITRIC OXIDE RELEASING DERIVATIVES OF PARACETAMOL NOS2, NOS3, NOS1 FAAH 1072/4885LMNA 4730/4885SMN1; SMN2 4739/4885
US-20070078146-A1 Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma MAPK1, MAPK3, MAPK4 FAAH 1086/4885LMNA 4386/4885SMN1; SMN2 2049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.